Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.
anti-tumor drug
cancer
diabetes mellitus
immune checkpoint inhibitor
phosphatidylinositol-3-kinase inhibitor
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
06
2023
accepted:
17
08
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabetes mellitus are common side effects of anti-tumor drug use that present mainly as hyperglycemia. Here, we present two case reports of diabetes mellitus caused by the use of tremelimumab and apalutamide, respectively, in cancer treatment, and a comprehensive, comparative review of the literature on these forms of diabetes. Case 1 presented with diabetic ketoacidosis and was diagnosed with ICI-related diabetes mellitus and treated with insulin. Case 2 was diagnosed with PI3Ki-related diabetes mellitus, and her blood glucose level returned to normal with the use of metformin and dapagliflozin. We systematically searched the PubMed database for articles on ICI- and PI3Ki-related diabetes mellitus and characterized the differences in clinical features and treatment between these two forms of diabetes.
Identifiants
pubmed: 37732122
doi: 10.3389/fendo.2023.1236946
pmc: PMC10509015
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Phosphatidylinositols
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1236946Informations de copyright
Copyright © 2023 Gao, Zhong, Gan, Xiang, Li and Yan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Genet. 2015 Aug;47(8):898-905
pubmed: 26168013
J Oncol Pract. 2018 Apr;14(4):247-249
pubmed: 29517954
Diabetes Care. 2020 Dec;43(12):3106-3109
pubmed: 33051330
Cureus. 2021 Dec 29;13(12):e20817
pubmed: 35141074
Diabetes Care. 2015 Sep;38(9):1638-42
pubmed: 26294774
BMJ Case Rep. 2022 Jan 17;15(1):
pubmed: 35039353
Clin Chim Acta. 2018 Mar;478:162-165
pubmed: 29288641
Onco Targets Ther. 2022 Oct 28;15:1309-1315
pubmed: 36330532
Sci Rep. 2018 May 29;8(1):8295
pubmed: 29844327
Cureus. 2023 Feb 21;15(2):e35276
pubmed: 36825072
Acta Endocrinol (Buchar). 2022 Jan-Mar;18(1):115-117
pubmed: 35975254
Cancer. 2018 Mar 15;124(6):1111-1121
pubmed: 29313945
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-3154
pubmed: 29955867
Nat Cancer. 2021 Jun;2(6):587-597
pubmed: 35118422
Clin Med (Lond). 2020 Jul;20(4):417-423
pubmed: 32675150
Nature. 2018 Aug;560(7719):499-503
pubmed: 30051890
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9232-7
pubmed: 16754860
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Drugs. 2019 Apr;79(5):573-578
pubmed: 30805896
Ther Adv Med Oncol. 2020 Jul 28;12:1758835920940939
pubmed: 32782489
JCI Insight. 2022 Sep 8;7(17):
pubmed: 35925682
Oncoimmunology. 2015 Feb 3;4(5):e1002731
pubmed: 26155392
Int J Biol Sci. 2018 Aug 6;14(11):1483-1496
pubmed: 30263000
Cureus. 2021 Nov 5;13(11):e19295
pubmed: 34900474
Diabetologia. 2013 Mar;56(3):476-83
pubmed: 23238788
Physiol Rev. 2015 Jul;95(3):727-48
pubmed: 26084689
AACE Clin Case Rep. 2020 Sep 24;6(6):e349-e351
pubmed: 33244501
J Investig Med High Impact Case Rep. 2017 Aug 23;5(3):2324709617725351
pubmed: 28856166
Diabetol Int. 2018 Jul 03;10(1):58-66
pubmed: 30800564
Cureus. 2021 May 1;13(5):e14796
pubmed: 34084688
Cancer. 2019 Apr 1;125(7):1185-1199
pubmed: 30582752
Eur J Endocrinol. 2019 Sep;181(3):363-374
pubmed: 31330498
Endocr Rev. 2019 Feb 1;40(1):17-65
pubmed: 30184160
Sci Rep. 2020 Sep 23;10(1):15567
pubmed: 32968172
Clin Breast Cancer. 2020 Jun;20(3):e232-e243
pubmed: 32234362
Nature. 2022 Feb;602(7895):156-161
pubmed: 34847567
AACE Clin Case Rep. 2020 Dec 28;7(2):127-131
pubmed: 34095470
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5499-5506
pubmed: 31265074
Integr Cancer Ther. 2022 Jan-Dec;21:15347354211073163
pubmed: 35075945
Pediatr Diabetes. 2018 May;19(3):346-353
pubmed: 29094512
Diabetes Metab Res Rev. 2017 Nov;33(8):
pubmed: 28736981
Endocrinol Diabetes Metab Case Rep. 2023 Jun 21;2023(2):
pubmed: 37341461
Medicine (Baltimore). 2022 Sep 2;101(35):e30398
pubmed: 36107581
Endocr Rev. 2020 Feb 1;41(1):
pubmed: 31722374
BMJ Case Rep. 2016 Nov 23;2016:
pubmed: 27881588
Diabet Med. 2020 May;37(5):893-894
pubmed: 32096251
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221105249
pubmed: 35712858